[go: up one dir, main page]

PL3377534T3 - Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4 - Google Patents

Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4

Info

Publication number
PL3377534T3
PL3377534T3 PL16819718.4T PL16819718T PL3377534T3 PL 3377534 T3 PL3377534 T3 PL 3377534T3 PL 16819718 T PL16819718 T PL 16819718T PL 3377534 T3 PL3377534 T3 PL 3377534T3
Authority
PL
Poland
Prior art keywords
antibody
ctla
treatment
combination
lung cancer
Prior art date
Application number
PL16819718.4T
Other languages
English (en)
Inventor
Nathan E. FAITH
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3377534T3 publication Critical patent/PL3377534T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL16819718.4T 2015-11-18 2016-11-18 Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4 PL3377534T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257139P 2015-11-18 2015-11-18
US201662345314P 2016-06-03 2016-06-03
PCT/US2016/062884 WO2017087870A1 (en) 2015-11-18 2016-11-18 Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
PL3377534T3 true PL3377534T3 (pl) 2025-09-01

Family

ID=57680484

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819718.4T PL3377534T3 (pl) 2015-11-18 2016-11-18 Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4

Country Status (17)

Country Link
US (3) US11072657B2 (pl)
EP (2) EP3377534B1 (pl)
JP (3) JP2018538263A (pl)
KR (1) KR20180071386A (pl)
CN (1) CN108350081A (pl)
DK (1) DK3377534T3 (pl)
ES (1) ES3034582T3 (pl)
FI (1) FI3377534T3 (pl)
HR (1) HRP20250902T1 (pl)
LT (1) LT3377534T (pl)
PL (1) PL3377534T3 (pl)
PT (1) PT3377534T (pl)
RS (1) RS67037B1 (pl)
SI (1) SI3377534T1 (pl)
SM (1) SMT202500282T1 (pl)
TW (3) TWI821748B (pl)
WO (1) WO2017087870A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
NZ735820A (en) * 2015-04-17 2025-02-28 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
LT3377534T (lt) 2015-11-18 2025-08-11 Bristol-Myers Squibb Company Plaučių vėžio gydymas, panaudojant anti-pd-1 antikūno ir anti ctla-4 antikūno derinį
EP4491237A3 (en) * 2016-10-28 2025-03-26 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
CA3081696A1 (en) * 2017-11-07 2019-05-16 Memorial Sloan Kettering Cancer Center Inhibition of ctla-4 and/or pd-1 for regulation of t cells
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020185739A1 (en) * 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
AU2020234785A1 (en) * 2019-03-13 2021-08-19 Merck Sharp & Dohme Llc Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents
US20220195046A1 (en) * 2019-03-28 2022-06-23 Bristol-Myers Squibb Company Methods of treating tumor
US20220041733A1 (en) * 2019-03-28 2022-02-10 Bristol-Myers Squibb Company Methods of treating tumor
CN115812081A (zh) * 2020-07-21 2023-03-17 上海君实生物医药科技股份有限公司 抗ctla-4抗体及其用途
EP4294531A4 (en) * 2021-02-18 2025-07-16 Qilu Puget Sound Biotherapeutics Corp COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES
CN119300862A (zh) * 2022-06-28 2025-01-10 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8263073B2 (en) * 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2777226A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US9107887B2 (en) 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2879498A4 (en) * 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014066532A1 (en) * 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
US20170158776A1 (en) 2014-05-15 2017-06-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
AU2016256455A1 (en) * 2015-04-30 2017-12-07 Adaptive Biologix, Inc. Extracellular matrix compositions for the treatment of cancer or immunological diseases
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
PL3322731T3 (pl) * 2015-07-14 2021-05-31 Bristol-Myers Squibb Company Sposób leczenia raka inhibitorem immunologicznych punktów kontrolnych; przeciwciałem, które wiąże się z receptorem programowanej śmierci-1 (pd-1) lub ligandem receptora programowanej śmierci 1 (pd-l1)
LT3377534T (lt) * 2015-11-18 2025-08-11 Bristol-Myers Squibb Company Plaučių vėžio gydymas, panaudojant anti-pd-1 antikūno ir anti ctla-4 antikūno derinį
US20210206854A1 (en) 2016-01-27 2021-07-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP7069032B2 (ja) * 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
JP2019517498A (ja) * 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
KR20250107295A (ko) 2016-06-03 2025-07-11 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
KR20210081384A (ko) * 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법

Also Published As

Publication number Publication date
JP2025029025A (ja) 2025-03-05
JP2022068352A (ja) 2022-05-09
FI3377534T3 (fi) 2025-08-22
JP2018538263A (ja) 2018-12-27
US20180371092A1 (en) 2018-12-27
EP3377534A1 (en) 2018-09-26
TW201731527A (zh) 2017-09-16
US20250154257A1 (en) 2025-05-15
US20220017619A1 (en) 2022-01-20
KR20180071386A (ko) 2018-06-27
SI3377534T1 (sl) 2025-09-30
EP4609915A2 (en) 2025-09-03
DK3377534T3 (da) 2025-08-18
WO2017087870A1 (en) 2017-05-26
ES3034582T3 (en) 2025-08-20
EP3377534B1 (en) 2025-06-18
TW202408573A (zh) 2024-03-01
HRP20250902T1 (hr) 2025-09-26
RS67037B1 (sr) 2025-08-29
TWI795347B (zh) 2023-03-11
EP4609915A3 (en) 2025-11-19
CN108350081A (zh) 2018-07-31
PT3377534T (pt) 2025-07-10
TWI821748B (zh) 2023-11-11
LT3377534T (lt) 2025-08-11
SMT202500282T1 (it) 2025-09-12
TW202227132A (zh) 2022-07-16
US11072657B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
IL308805B2 (en) Anti-PD-1 antibodies for the treatment of lung cancer
PT3377534T (pt) Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4
IL282962A (en) Anti-PD-1 antibodies and methods of using them
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL276481B (en) Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
IL259924A (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL259713B1 (en) Anti-DR5 antibodies and methods of using them
IL252280A0 (en) Anti pd-1 antibodies and methods of using them
SG10201913500TA (en) Anti-ctla-4 antibodies and methods of use thereof
LT4339615T (lt) Antikūnai prieš pd-1, skirti naudoti vėžio gydymui
IL256439A (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
IL307850A (en) A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
HK40018984A (en) Anti-pd-1 antibodies for treatment of lung cancer